UK Authorization for Aflibercept   - Scorecard - MDSpire

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Share

Clinical Scorecard: UK Authorization for Aflibercept

At a Glance

CategoryDetail
ConditionVisual impairment due to macular edema secondary to retinal vein occlusion (RVO)
Key MechanismsAnti-VEGF therapy
Target PopulationTreatment-naïve patients with RVO
Care SettingOphthalmology clinics

Key Highlights

  • Aflibercept 8 mg approved for RVO treatment in the UK
  • Based on Phase III QUASAR trial data
  • 8 mg formulation shows non-inferior visual acuity gains compared to 2 mg
  • Patients on 8 mg require fewer injections over time
  • Durability of treatment intervals improved with 8 mg regimen

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of RVO confirmed through clinical examination and imaging

Management

  • Initiate treatment with aflibercept 8 mg after diagnosis

Monitoring & Follow-up

  • Regular assessment of visual acuity and anatomical outcomes

Risks

  • Monitor for potential adverse effects consistent with anti-VEGF therapy

Patient & Prescribing Data

Patients with visual impairment due to RVO

Aflibercept 8 mg may reduce treatment burden while maintaining efficacy

Clinical Best Practices

  • Consider higher-dose aflibercept for patients requiring intensive early treatment
  • Evaluate treatment intervals based on patient response and fluid reduction

Related Resources & Content

Original Source(s)

UK Authorization for Aflibercept  

  • March 3, 2026

Related Content

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

AI in Retina: Accuracy First

Ophthalmic patients want accuracy in their clinical decisions, regardless of who makes that decision

  • February 3, 2026

  • 2 min